FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary...

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Barrettsesophagus--Castle Biosciences has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher Barrett's Es...

These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's Compensation Committee of its Board of Directors granted restricted stock units (RSUs) as inducement material to new employee...

Here, we present four stocks, CSTL, QFIN, ESEA and STRA, with solid net profit margins that can contribute toward making a strong portfolio.

The average of price targets set by Wall Street analysts indicates a potential upside of 42% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, t...

These five small cap stocks have strong growth potential for 2025. These are: TALK, RYAM, CSTL, PBAM, RSSS.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's executive management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Dec. 4, 2024, ...

If you are looking for stocks that are well positioned to maintain their recent uptrend, Castle Biosciences (CSTL) could be a great choice. It is one of the several stocks that passed through our "Rec...

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP24--Castle will share new data highlighting the clinical performance of its DecisionDx-Melanoma and MyPath Melanoma tests at the ASDP 61st Annual Mee...

Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, Presi...

Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.26 per share a year ...

Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ACG2024--New data at ACG 2024 demonstrates ability of TissueCypher to significantly reduce healthcare costs associated with management of Barrett's esoph...

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announces that its executive management is scheduled to present a company overview at three investor conferences in November.

Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thr...

Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle will share new data at ASDS supporting the clinical utility of its DecisionDx-Melanoma and DecisionDx-SCC tests.